期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 165, 期 3, 页码 741-753出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1476-5381.2011.01603.x
关键词
Cardamonin; TRAIL; apoptosis; death receptors; ROS
资金
- National Institutes of Health [CA-16672, NIH CA-124787-01A2]
- Center for Targeted Therapy of MD Anderson Cancer Center
BACKGROUND AND PURPOSE TNF-related apoptosis-inducing ligand (TRAIL) is currently in clinical trials as a treatment for cancer, but development of resistance is a major drawback. Thus agents that can overcome resistance to TRAIL are urgently needed. Cardamonin (2',4'-dihydroxy-6'-methoxychalcone) has been shown to affect cell growth by modulating various cell signalling pathways. Hence, we investigated the effect of cardamonin on the actions of TRAIL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据